Related Experiment Videos
Lipoprotein metabolism and renal failure
P O Attman1, O Samuelsson, P Alaupovic
1Department of Nephrology, University of Göteborg, Sweden.
Summary
Renal disease alters lipoprotein metabolism, causing dyslipoproteinemia even without hyperlipidemia. This condition affects both HDL and LDL, potentially increasing atherosclerosis risk in chronic kidney disease patients.
Area of Science:
- Nephrology
- Lipidology
- Biochemistry
Background:
- Lipoprotein metabolism is frequently altered in patients with renal insufficiency and renal failure.
- Dyslipoproteinemia in renal disease presents characteristic abnormalities in apolipoprotein profiles and lipoprotein composition.
- These changes develop during asymptomatic stages and worsen with advancing renal failure.
Purpose of the Study:
- To characterize the specific abnormalities in lipoprotein metabolism and transport in patients with renal insufficiency.
- To investigate the impact of these alterations on lipoprotein composition and catabolism.
- To explore the potential pathophysiologic links and clinical consequences of renal dyslipoproteinemia.
Main Methods:
- Analysis of apolipoprotein (apo) profiles and lipoprotein composition in patients with varying degrees of renal insufficiency.
- Assessment of lipoprotein transport, focusing on the catabolism of apoB-containing lipoproteins.
- Evaluation of high-density lipoprotein (HDL) components, including cholesterol, apoA-I, apoA-II, and HDL2/HDL3 ratio.
Main Results:
- Moderate hypertriglyceridemia is a characteristic finding.
- Decreased catabolism of apoB-containing lipoproteins due to reduced lipolytic enzyme activity and altered composition.
- Increased levels of intermediate-density lipoproteins and triglyceride-enriched low-density lipoproteins, with elevated apoC-III and apoE.
- Decreased concentrations of cholesterol, apoA-I, and apoA-II in HDL, leading to reduced HDL2/HDL3 ratio.
- Characteristic decrease in the apoA-I to apoC-III ratio and the anti-atherogenic apoA-I/apoB index.
Conclusions:
- Renal dyslipoproteinemia is a complex condition characterized by altered lipoprotein metabolism and composition, affecting both LDL and HDL.
- The primary defect involves decreased catabolism of apoB-containing lipoproteins, leading to an atherogenic lipid profile.
- This dyslipoproteinemia may contribute to the progression of atherosclerotic vascular disease and renal function deterioration.
- While interventions may ameliorate uremic dyslipoproteinemia, their long-term clinical effects require further investigation.